$637.56
0.21% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US04016X1019
Symbol
ARGX

argenx SE ADR Stock price

$637.56
+76.28 13.59% 1M
-11.53 1.78% 6M
+22.56 3.67% YTD
+99.39 18.47% 1Y
+260.65 69.15% 3Y
+405.42 174.64% 5Y
+614.56 2,672.00% 10Y
+614.56 2,672.00% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-1.34 0.21%
ISIN
US04016X1019
Symbol
ARGX
Industry

Key metrics

Basic
Market capitalization
$40.4b
Enterprise Value
$36.5b
Net debt
positive
Cash
$3.9b
Shares outstanding
61.2m
Valuation (TTM | estimate)
P/E
32.8 | 54.6
P/S
13.2 | 10.9
EV/Sales
12.0 | 9.9
EV/FCF
118.3
P/B
6.6
Financial Health
Equity Ratio
88.7%
Return on Equity
15.2%
ROCE
7.6%
ROIC
33.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.1b | $3.7b
EBITDA
$488.8m | $808.8m
EBIT
$466.6m | $769.1m
Net Income
$1.3b | $716.1m
Free Cash Flow
$308.7m
Growth (TTM | estimate)
Revenue
- | 69.1%
EBITDA
- | 17,455.2%
EBIT
- | 5,589.4%
Net Income
- | -14.0%
Free Cash Flow
194.9%
Margin (TTM | estimate)
Gross
89.4%
EBITDA
16.0% | 21.8%
EBIT
15.3%
Net
42.0% | 19.3%
Free Cash Flow
10.1%
More
EPS
$19.5
FCF per Share
$5.0
Short interest
3.3%
Employees
2k
Rev per Employee
$1.4m
Show more

Is argenx SE ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

argenx SE ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a argenx SE ADR forecast:

23x Buy
92%
2x Hold
8%

Analyst Opinions

25 Analysts have issued a argenx SE ADR forecast:

Buy
92%
Hold
8%

Financial data from argenx SE ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,051 3,051
-
100%
- Direct Costs 323 323
-
11%
2,728 2,728
-
89%
- Selling and Administrative Expenses 1,165 1,165
-
38%
- Research and Development Expense 1,170 1,170
-
38%
489 489
-
16%
- Depreciation and Amortization 22 22
91% 91%
1%
EBIT (Operating Income) EBIT 467 467
-
15%
Net Profit 1,280 1,280
-
42%

In millions USD.

Don't miss a Thing! We will send you all news about argenx SE ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

argenx SE ADR Stock News

Neutral
GlobeNewsWire
about 13 hours ago
Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life
Neutral
Seeking Alpha
5 days ago
Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses, guidance cuts, and Medicare Advantage mispricing, despite its long-term potential to restore profitability. Thermo Fisher and argenx detracted from performance amid macro headwinds and lower-than...
Neutral
Seeking Alpha
12 days ago
argenx SE (NASDAQ:ARGX ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Karen Massey - Chief Operating Officer Karl Gubitz - Chief Financial Officer Luc Truyen - Chief Medical Officer Timothy Van Hauwermeiren - Co-Founder, CEO & Executive Director Conference Call Participants Aka...
More argenx SE ADR News

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,599
Founded 2008
Website www.argenx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today